Universal GPCR Activity Sensor for Next Generation Drug Discovery

This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.

Subsidie
€ 2.965.384
2023

Projectdetails

Introduction

This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic targets, both for current drugs and those under development, covering about a third of the €1.2 trillion pharmaceutical market.

Background

Recent research has revealed that GPCRs do not function as simple on/off switches but instead can adopt multiple conformations leading to complex textures of downstream effects. Functionally selective drugs modulate the GPCR structure to stimulate certain downstream pathways over others.

Current Challenges

In the search for this next generation of better drugs, the pharmaceutical industry currently employs multiple (10+) distinct GPCR assays, performed in non-identical cellular contexts. Misleading readouts from this approach contribute significantly to costly drug failure.

Proposed Solution

Here we propose a radically new single-assay technology platform that will enable detection and functional classification of drug candidates with superior confidence compared to today's approaches. Its unique design supports streamlined drug discovery from the test tube to the native disease-relevant cell, as well as the capacity to efficiently harness artificial intelligence (AI) in the design of better drugs.

Technology Overview

The technology is based upon highly informative fluorescent sensor reagents that react to different receptor conformations with subtle, flexible changes in their structure.

Objectives

In this Pathfinder project, our main objective is to demonstrate that the conformational fingerprints generated by these sensors correlate to specific cellular signalling profiles, i.e. GPCR activity states (proof of principle).

Future Impact

We believe that the UniSens platform will become the standard tool for early drug development and could be a game-changer in the search for safer, more effective drugs.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.965.384
Totale projectbegroting€ 2.965.384

Tijdlijn

Startdatum1-11-2023
Einddatum31-10-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • ISAR BIOSCIENCE GmbHpenvoerder
  • CELTARYS RESEARCH SL
  • UNIVERZITA KARLOVA
  • INNOVATIVE BIOIMAGING SRO
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
  • STICHTING VU
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
  • INTERAX BIOTECH AG

Land(en)

GermanySpainCzechiaFranceNetherlandsSwitzerland

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

€ 2.998.878

Vergelijkbare projecten uit andere regelingen

ERC Starting...

Decoding the Molecular Logic of GPCR Signaling

SignAlloMod aims to decode GPCR signaling logic at the single-molecule level using a novel method to enhance drug discovery and pharmacological interventions.

€ 1.499.389
ERC Starting...

Molecular mechanisms of GPCR heteromers signaling

This project aims to elucidate the molecular mechanisms of GPCR heteromer assembly and signaling, focusing on the mGlu2-5HT2A complex to advance drug development for schizophrenia.

€ 1.499.494
ERC Advanced...

Protein function regulation through inserts for response to biological, chemical and physical signals

This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.

€ 2.500.000
EIC Accelerator

The ProM platform: New ways to drug the undruggable

PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.

€ 2.461.375
ERC Consolid...

Development of Suprasensors and Assays for Molecular Diagnostics

SupraSense aims to develop advanced biomimetic sensors for detecting metabolites in biofluids, enhancing diagnostic selectivity and sensitivity for early disease detection.

€ 1.994.069